FLOLAN

This brand name is authorized in United States. It is also authorized in Australia, Austria, Canada, Estonia, Ireland, Israel, Japan, Malta, Netherlands, Singapore, Spain, UK.

Active ingredients

The drug FLOLAN contains one active pharmaceutical ingredient (API):

1	Epoprostenol UNII 4K04IQ1OF4 - EPOPROSTENOL SODIUM
	Epoprostenol sodium, the monosodium salt of epoprostenol, a naturally occurring prostaglandin produced by the intima of blood vessels. Epoprostenol is the most potent inhibitor of platelet aggregation known. It is also a potent vasodilator.
	Read more about Epoprostenol

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
B01AC09	Epoprostenol	B Blood and blood forming organs → B01 Antithrombotic agents → B01A Antithrombotic agents → B01AC Platelet aggregation inhibitors excl. heparin
Discover more medicines within B01AC09
C01DX	Other vasodilators used in cardiac diseases	C Cardiovascular system → C01 Cardiac therapy → C01D Vasodilators used in cardiac diseases
Discover more medicines within C01DX

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	11065J, 11069N, 11082G, 11090Q
CA	Health Products and Food Branch	02230845, 02230848
EE	Ravimiamet	1043514, 1875179
ES	Centro de información online de medicamentos de la AEMPS	57757
GB	Medicines & Healthcare Products Regulatory Agency	335926, 335935
IE	Health Products Regulatory Authority	88748, 88751
IL	מִשְׂרַד הַבְּרִיאוּת	8255, 8256
JP	医薬品医療機器総合機構	2190413F1028, 2190413F2024, 2190413F3020, 2190413F4027
MT	Medicines Authority	MA192/02901, PI565/85402A
NL	Z-Index G-Standaard	14278707, 14278715, 14278723, 14286122
NL	Z-Index G-Standaard, PRK	33898, 52809
SG	Health Sciences Authority	02241P
US	FDA, National Drug Code	0173-0517, 0173-0519